An Observational Study of Predictors and Outcomes of Lung Cancer in Never-smokers in the UK
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College London Hospitals
About this trial
The goal of this observational study is to improve the early detection of lung cancer in adults who have smoked less than 100 tobacco cigarettes ("never-smokers") in the United Kingdom. The main questions it aims to answer are:
* To describe characteristics such as demographics, co-morbidities and environmental exposures * To describe participant pathways including presentation mode and symptoms to understand if earlier diagnosis would be possible * To describe participant outcomes such as cancer stage, treatment and mortality * To quantitatively or qualitatively measure modifiable and non-modifiable factors that may be associated with LCINS including environmental measures, blood tests and genomic data.
Participants will currently have no change to their usual care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All adult participants from age of 18 who are diagnosed or treated with primary lung cancer through radiology or histology at any participating study site
Disqualifiers
More than 100 cigarettes or 75g tobacco in their lifetime
Those who have received a prescription for nicotine replacement therapy
For prospective participants, those who cannot consent will be excluded
Trial population
This study will aim to recruit participants who have been diagnosed or treated with primary lung cancer at any participating study site.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Demographics, comorbidities and environmental exposures of participants
From review of electronic health records
Time frame
Comorbidities and environmental exposures at diagnosis (approximately up to 156 weeks prior to diagnosis)2
Participant pathways including presentation mode and symptoms
From review of electronic health records
Time frame
Presentation mode and symptoms at time of diagnosis (approximately up to 52 weeks prior to diagnosis)Secondary outcomes
1
Participant outcomes such as cancer stage, treatment, mortality
From review of electronic health records
Time frame
Cancer stage at time of diagnosis, treatment and mortality through study completion (likely 5 years)2
Measurement of modifiable and non-modifiable factors associated with LCINS
To be determined
Time frame
Through study completion (likely 5 years)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University College London Hospitals
Lead sponsor
University College, London
Sponsor institution
Source ClinicalTrials.gov